[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100617587":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":34,"responsibleParty":120,"collaborators":19,"id":123,"slug":124,"hasResults":125,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":125,"sex":131,"minAge":132,"maxAge":19,"enrollmentInfo":133,"targetDuration":19,"studyType":136,"phases":137,"briefSummary":139,"conditions":140,"keywords":142,"overallStatus":37,"whyStopped":19,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":159},{"fullName":5,"class":6},"German Heart Institute","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Non-invasive mapping-guided ablation","EXPERIMENTAL","In this arm patients undergo a personalized ablation approach: In addition to conventional pulmonary vein isolation, additional target regions will be ablated based on non-invasive global mapping.",[13],"Procedure: Non-invasive mapping-guided ablation",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"PROCEDURE","The study intervention consists of\n\n1. Empirical pulmonary vein isolation (current standard of care) plus\n2. A personalized ablation approach targeting up to three additional atrial regions which harbour critical AF-perpetuating sources:\n\n   * Target regions are selected based on the temporal Stability of local Atrial High-Rate Activity (SAHRA) using a non-invasive global mapping system (Acorys, Corify Care). Local high-rate activity is confirmed by endocardial mapping.\n   * Selected target regions displaying stable high-rate activity are isolated or homogenized according to predefined regional borders based on the 15-segment bi-atrial model of the EHRA and EACVI Clinical Consensus on Standardized Atrial Regionalization (Althoff et al. 2025).",[9],null,[21],{"name":22,"affiliation":23,"role":24},"Till F Althoff, M.D.","German Heart Center of the Charitè, Berlin, Department of Cardiology, Angiology and Intensive Care Medicine","PRINCIPAL_INVESTIGATOR",[26,30],{"name":22,"role":27,"phone":28,"phoneExt":19,"email":29},"CONTACT","0049 30 450613163","till.althoff@dhzc-charite.de",{"name":31,"role":27,"phone":32,"phoneExt":19,"email":33},"Gerhard Hindricks, M.D.","030450613163","gerhard.hindricks@dhzc-charite.de",[35,52,70,87,105],{"facility":36,"status":37,"city":38,"state":19,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"German Heart Center of the Charité, Charité University Hospital Berlin","RECRUITING","Berlin","10117","Germany","DE",{"type":43,"coordinates":44},"Point",[45,46],13.41053,52.52437,{"lat":46,"lon":45},[49,50,51],{"name":22,"role":27,"phone":28,"phoneExt":19,"email":29},{"name":19,"role":27,"phone":19,"phoneExt":19,"email":29},{"name":22,"role":24,"phone":19,"phoneExt":19,"email":19},{"facility":53,"status":54,"city":55,"state":19,"zip":56,"country":40,"countryCode":41,"cosmosGeoPoint":57,"geoPoint":61,"contacts":62},"Frankfurt University Heart and Vascular Center","NOT_YET_RECRUITING","Frankfurt am Main","60598",{"type":43,"coordinates":58},[59,60],8.68417,50.11552,{"lat":60,"lon":59},[63,67,69],{"name":64,"role":27,"phone":65,"phoneExt":19,"email":66},"Reza Wakili, M.D.","0049 69 63017404","reza.wakili@herz-frankfurt.de",{"name":19,"role":27,"phone":19,"phoneExt":19,"email":68},"Reza.Wakili@unimedizin-ffm.de",{"name":64,"role":24,"phone":19,"phoneExt":19,"email":19},{"facility":71,"status":54,"city":72,"state":19,"zip":73,"country":74,"countryCode":75,"cosmosGeoPoint":76,"geoPoint":80,"contacts":81},"Central Lisbon University Hospital Centre (CHULC), Hospital de Santa Marta","Lisbon","1169-024","Portugal","PT",{"type":43,"coordinates":77},[78,79],-9.1498,38.72509,{"lat":79,"lon":78},[82,86],{"name":83,"role":27,"phone":84,"phoneExt":19,"email":85},"Mario Martins Oliveira, M.D.","0035 121 3594000","m.martinsoliveira@gmail.com",{"name":83,"role":24,"phone":19,"phoneExt":19,"email":19},{"facility":88,"status":54,"city":89,"state":19,"zip":90,"country":91,"countryCode":92,"cosmosGeoPoint":93,"geoPoint":97,"contacts":98},"Hospital Clinic, University of Barcelona","Barcelona","08036","Spain","ES",{"type":43,"coordinates":94},[95,96],2.15899,41.38879,{"lat":96,"lon":95},[99,103],{"name":100,"role":27,"phone":101,"phoneExt":19,"email":102},"Ivo Roca-Luque, M.D. Ph.D.","0034 93 2271778","iroca@clinic.cat",{"name":104,"role":24,"phone":19,"phoneExt":19,"email":19},"Ivo Roca-Luque, M.D.",{"facility":106,"status":54,"city":107,"state":19,"zip":108,"country":91,"countryCode":92,"cosmosGeoPoint":109,"geoPoint":113,"contacts":114},"Gregorio Marañón General University Hospital","Madrid","28007",{"type":43,"coordinates":110},[111,112],-3.70256,40.4165,{"lat":112,"lon":111},[115,119],{"name":116,"role":27,"phone":117,"phoneExt":19,"email":118},"Felipe Atienza, M.D.","0034 915 86 80 00","felipe.atienza@salud.madrid.org",{"name":116,"role":24,"phone":19,"phoneExt":19,"email":19},{"type":24,"investigatorFullName":121,"investigatorTitle":122,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"Till Althoff","Head of Research and Principal Investigator","100617587","personalized-atrial-fibrillation-ablation-guided-by-non-invasive-global-mapping-100617587",false,"NCT07320560","Personalized Atrial Fibrillation Ablation Guided by Non-Invasive Global Mapping","Personalized Atrial Fibrillation Ablation Guided by Non-Invasive Global Mapping - the CURE-AF Pilot Study","CURE-AF","Inclusion Criteria:\n\nAblation-naïve patients with:\n\n1. Persistent AF planned for catheter ablation plus\n2. Left atrial enlargement (LA diameter ≥45 mm or LA volume index ≥35ml\u002Fm2 or LA area ≥20 cm2)\n\nExclusion Criteria:\n\n* Previous cardiac ablation\n* Age \\\u003C18 years\n* Pregnancy or lactation\n* Previous stroke\u002FTIA\n* Severe left ventricular dysfunction (LVEF \\\u003C35%)\n* Renal failure (GFR \\\u003C30 ml\u002Fmin)\n* Dermal disease or hypersensitivity predisposing for skin irritation or exanthema","ALL","18 Years",{"count":134,"type":135},45,"ESTIMATED","INTERVENTIONAL",[138],"NA","This pilot study investigates if non-invasive global mapping can guide catheter ablation of atrial fibrillation (AF) by defining personalized targets based on the temporal Stability of local Atrial High-Rate Activity (SAHRA). The study also assesses efficacy and safety of this approach and evaluates potential signals of harm. The main questions it aims to answer are:\n\n* Does ablation of targets defined by non-invasive global mapping improve rates of acute atrial fibrillation termination?\n* Does such a personalized ablation approach reduce arrhythmia recurrence rates? Researchers will compare the results of the personalized ablation approach with comparable patients that had undergone a conventional \"empirical\" ablation approach (pulmonary vein isolation).\n\nParticipants will:\n\n* Undergo a personalized catheter ablation approach employing both a non-invasive global mapping system and a conventional intracardiac mapping system\n* Visit the clinic 3, 6 and 12 months after ablation for clinical follow-up\n* Schedule a telephone visit 9 and 24 months after ablation for clinical follow-up",[141],"Atrial Fibrillation (AF)",[143,144,145,146,147,148,149],"Atrial Fibrillation","Catheter Ablation","Non-invasive mapping","Global Mapping","Electrocardiographic Imaging","Body Surface Mapping","Atrial fibrillation drivers","2025-12-25",{"date":152,"type":153},"2026-01-06","ACTUAL",{"date":155,"type":135},"2026-01-15",{"date":157,"type":135},"2027-12-31",{"name":5,"class":6},5]